Reuters logo
AstraZeneca sells two heart drugs to China Medical for $500 mln
February 29, 2016 / 8:26 AM / 2 years ago

AstraZeneca sells two heart drugs to China Medical for $500 mln

LONDON, Feb 29 (Reuters) - AstraZeneca said on Monday it had sold the rights to two ageing heart drugs to China Medical System Holdings for $500 million, marking the latest step in an ongoing programme of divestments for non-core assets.

Chief Executive Pascal Soriot is relying heavily on so-called externalisation deals to raise cash and cushion profits during a period of patent expiries on older blockbusters and high investment in new medicines.

China Medical will pay AstraZeneca $310 million for a licence to sell blood pressure medicine Plendil in China, although the British-based company will still manufacture the drug and retain global rights outside China.

Plendil was first approved in China in 1995 and had sales in 2015 of $189 million.

The Chinese group is also paying $190 million for global rights to angina treatment Imdur outside the United States. Imdur’s global sales outside the U.S. were $57 million last year.

AstraZeneca said the deals would not impact its financial guidance for 2016. (Reporting by Ben Hirschler; Editing by Keith Weir)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below